Two major catalysts on the horizon could send Omeros' stock soaring. What should investors think?
News & Analysis: Omeros
The company reported full-year 2019 operating results and a separate update from the pipeline.
Single-arm trial data for narsoplimab isn't nearly as exciting as it used to be.
The small biotech received good news from the FDA.
The struggling drug developer reported third-quarter 2018 operating results and raised $210 million in debt.
It appears that an unproven approach to treating rare blood disorders will remain that way.
Investors are picking up the pieces after the biotech's bad news on Monday.
Pipeline progress outlined during the company's first-quarter report lifted spirits.
A few pages in a gigantic spending bill could allow the Omidria train to start rolling again.
A bearish investor report casts doubt on the future of the company's main source of revenue.
Rising sales and upbeat clinical news have left investors feeling optimistic.